BioSpace News Archive

Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $100M. The PRV was granted to Rhythm by the U.S. Food and Drug Administration (FDA) with the approval of IMCIVREE™ (setmelanotide) for chronic w

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company’s Chief Executive Officer and President, will present at the 39 th Annual J.P. Morgan Virtual Healthcare Conference on Tuesday, January 12, 2021 at 2:50 pm EST. The live and archived webcast of the presentation wi

Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in three virtual investor conferences in January 2021.

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar , Anixa’s Chief Executive Officer, will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14 , 2021.

Chemomab Ltd., a clinical-stage biotech company focusing on discovery and development of innovative therapeutics for fibrosis-related diseases, today announces positive results of the phase Ib clinical trial of its lead compound CM-101 in nonalcoholic fatty liver disease (NAFLD) patients with normal liver function.

Industry Veteran Brings Over Three Decades of Experience Across Global Healthcare Landscape

BioMarin Pharmaceutical Inc. announced that management will participate in two upcoming virtual conferences.

A Global Leader in Research and Education Accelerates its Strategy to Power the World’s Knowledge Ecosystem by Acquiring a Fast-Growing Innovator in Open Access

DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 39 th annual J.P. Morgan Healthcare Conference on January 11, 2021. The live presentation, which will occur virtually, is scheduled to begin at approximately 11:40 AM EST and will be concurrently webcast. The link to the webcast will be available on the Dexcom IR

Nxt-ID, Inc., a provider of healthcare devices and services, announced that on January 4, 2021, it received written notice from the Office of General Counsel of The Nasdaq Stock Market LLC confirming that the Company has regained compliance with the applicable Nasdaq minimum bid price continued listing requirement and the matter is now closed.